evaluation of the accuracy of inr results from patients taking phenprocoumon as anticoagulant when measured using the lumiradx inr test

Conditions: Anticoagulants and Bleeding Disorders

Summary: this study is to evaluate the inr levels in patients taking phenprocoumon using the lumiradx point of care inr test and comparing the results to the laboratory reference method , the acl elite pro. comparison will also be made with the roche coaguchek point of care inr test (point of care reference method). performance will be demonstrated across a subject population of adult males and females in receipt of phenprocoumon vka therapy. this population is representative of the indications for use of the ce marked product. operators will be trained clinical site staff. venous plasma and capillary whole blood samples will be obtained from each subject in order to assess accuracy of the the lumiradx platform when compared to the reference devices (acl elite and coaguchek pro).

vitamin k antagonists (vka) are a group of substances that reduce blood clotting by reducing the action of vitamin k. they are used in anticoagulant medications in the prevention of thrombosis. the drugs work by depleting the active form of the vitamin by inhibiting vitamin k epoxide reductase and thus the recycling of inactive vitamin k back to the active reduced form. the most widely prescribed vkas are coumarins. this group is composed of several different structurally similar molecules and includes warfarin (coumadin), acenocoumerol and phenprocoumon. within the eu there are country to country differences in preferential vka prescription (1). in germany and surrounding countries, phenprocoumon (marketed as marcoumar or marcumar) is the most commonly prescribed. the majority of data supporting the development and validation of the lumriadx inr test has used samples form patients taking warfarin. the aim of this study is to evaluate the inr levels in patients taking phenprocoumon using the lumiradx point of care inr test and comparing the results to the laboratory reference method , the acl elite pro. comparison will also be made with the roche coaguchek point of care inr test (point of care reference method). this study is an observational, cross-sectional study with 100 patients in total. devices used in this study are ce marked for inr measurement by healthcare professionals. this study will be conducted according to the principles of good clinical practice (ich gcp e6(r2)), international conference on harmonization guidelines as applicable to devices, applicable geographical regulations and institutional research policies and procedures. for part 1 of the study (25 patients), one venous whole blood draw will be performed (\~9ml) into two anti-coagulated collection tubes (2 x 4.5ml 3.2% trisodium citrate). these tubes will then by processed to plasma by centrifugation, stored in eppendorf tubes, labelled and frozen at -80ºc . these will then be transferred to the lumriadx laboratory in scotland, uk, for subsequent measurement of inr with the reference device il acl elite pro coagulation analyzer (acl) and with the lumiradx poc inr test. for part 2 of the study (75 patients), one finger-stick sample of capillary blood (\~10µl/sample) from each subject, will be applied directly to a unique test strip for immediate measurement of inr on the lumiradx instrument. one further fingerstick sample is then obtained (\~10µl/sample) from a separate finger for immediate measurement of inr on the coaguchek pro. post-testing, samples will be disposed securely. from each patient, one venous whole blood draw will also be performed (\~9ml) into two anti-coagulated collection tubes (2 x 4.5ml 3.2% trisodium citrate). these tubes will then by processed to plasma by centrifugation, stored in eppendorf tubes, labelled and frozen at -80ºc. these will then be transferred to the lumiradx laboratory in scotland, uk, for subsequent measurement of inr with the reference device il acl elite pro coagulation analyzer (acl) and with the lumiradx poc inr test. inr results obtained will be used in comparative analyses of performance designed to meet the study objectives.

Eligibility criteria:
inclusion criteria: * persons \>18 years of age * willing and able to provide written informed consent and comply with study procedures * currently prescribed phenprocoumon vka therapy * deemed medically appropriate for study participation by the investigator exclusion criteria: * subject has previously participated in this part of the study * subject is within 4 weeks of first prescription of phenprocoumon * subject is taking a doac, or non-phenprocoumon vka therapy * confirmed or suspected pregnancy * vulnerable populations deemed inappropriate for study by the investigator * deemed medically inappropriate for study by the investigator (i.e. patients with a known inherited \[e.g. haemophilia or von willebrand's disease\] or acquired \[e.g. liver cirrhosis\] condition likely to be associated with a coagulopathy; or patients receiving non-vka anticoagulant medications)